Division of Pathology, Singapore General Hospital, Singapore.
Duke-NUS Medical School, Singapore.
Histopathology. 2019 Jun;74(7):970-987. doi: 10.1111/his.13837. Epub 2019 Mar 28.
Ductal carcinoma in situ (DCIS) of the breast is a heterogeneous disease that has risen to prominence and more recently controversy, with the advent of screening mammography. Debate concerning the true biological potential of low nuclear grade DCIS continues to challenge therapeutic considerations. In this study, we carried out a comprehensive literature review of the behaviour, outcomes and current management trials of low-grade DCIS, as well as a retrospective study of a large single institutional series of low-grade DCIS diagnosed at our hospital.
The study cohort comprised 195 cases of low-grade DCIS diagnosed at the Singapore General Hospital from 1994 to 2010. Clinicopathological parameters and follow-up data were retrieved and compared between screen-detected and symptomatic low-grade DCIS. Immunohistochemistry was performed for ER, PR and HER2. Among 195 cases, 123 (63.1%) were screen-detected, while 72 (36.9%) were symptomatic. Screen-detected cases had frequent calcifications (P < 0.001) and were smaller (P = 0.018) than symptomatic cases. All cases were ER-positive and rate of PR expression was high. No HER2 overexpression was observed. Mean and median follow-up periods were 107.8 and 109.6 months, respectively. Six patients recurred ipsilaterally, and one patient developed direct distant metastasis. One breast cancer-related death was recorded. Positive surgical margins (P = 0.023) were significantly associated with a higher risk of ipsilateral recurrences, as well as poorer disease-free survivals (P = 0.010).
Our data indicate that low-grade DCIS may be followed by invasive recurrences and even metastatic disease, requiring more study before being regarded as innocuous and indolent.
乳腺导管原位癌(DCIS)是一种异质性疾病,随着乳腺筛查钼靶摄影的出现,其发病率显著升高,也引发了更多的争议。关于低核级 DCIS 的真正生物学潜能的争论仍在挑战治疗方案的选择。本研究对低级别 DCIS 的行为、结局和当前治疗试验进行了全面的文献回顾,并对我院诊断的大样本单机构低级别 DCIS 系列进行了回顾性研究。
研究队列包括我院 1994 年至 2010 年间诊断的 195 例低级别 DCIS 患者。检索并比较了筛查检出与症状性低级别 DCIS 的临床病理参数和随访数据。对 ER、PR 和 HER2 进行免疫组化染色。195 例患者中,123 例(63.1%)为筛查检出,72 例(36.9%)为症状性。筛查检出的病例钙化更常见(P<0.001),肿瘤更小(P=0.018)。所有病例均为 ER 阳性,PR 表达率高。未观察到 HER2 过表达。平均和中位随访时间分别为 107.8 和 109.6 个月。6 例同侧复发,1 例发生远处转移。记录到 1 例乳腺癌相关死亡。阳性切缘(P=0.023)与同侧复发风险增加以及无病生存率降低(P=0.010)显著相关。
我们的数据表明,低级别 DCIS 可能会发生浸润性复发,甚至发生远处转移,在被视为良性和惰性病变之前,需要进一步研究。